Loading patent…
AssigneeBristol-Myers Squibb Company
InventorsAlejandro A. Aruffo, Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, H. Perry Fell, Jr.
Estimating the term…
Mixed specificity fusion proteins capable of binding to cellular adhesion molecules have been produced. The fusion proteins contain a polypeptide region, such as an IgG constant region, operatively attached to at least two binding regions each of which corresponds to either an extracellular domain of a cell surface receptor for cellular adhesion molecules, or a variable region of an antibody directed to a cellular adhesion molecule. A method of inhibiting inflammation is a patient is disclosed in which the present fusion proteins are administered to a patient to inhibit the attachment of inflammatory cells to vascular endothelium. A method of inhibiting metastasis is disclosed in which the present fusion proteins are administered to a patient to inhibit the metastasis of responsive tumor cells.
A substantially pure heterodimeric molecule comprising two chimeric chains, each of said chains comprising an immunoglobulin heavy chain constant domain and a binding region fir a cellular adhesion molecule wherein each chain has a binding region for a different cellular adhesion molecule and wherein the two chains of said heterodimeric molecule are associated via the immunoglobulin heavy chain constant domains.
A pharmacological composition comprising a heterodimeric molecule comprising two chimeric chains, each of said chains comprising an immunoglobulin heavy chain constant domain and a binding region for a cellular adhesion molecule wherein each chain has a binding region for a different cellular adhesion molecule and wherein the two chains of said heterodimeric molecule are associated via the immunoglobulin heavy chain constant domains.
Dependencies are inferred from the claim text.